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Abstract 
The WHO Biopharmaceutical Classification System (BCS) is a practical tool to identify active pharmaceutical 
ingredients (APIs) that scientifically qualify for a waiver of in vivo bioequivalence studies. The focus of this 
study was to engage a global network of laboratories to experimentally quantify the pH-dependent 
solubility of the highest therapeutic dose of 16 APIs using a harmonized protocol. Intra-laboratory 
variability was ≤5 %, and no apparent association of inter-laboratory variability with API solubility was 
discovered. Final classification “low solubility” vs “high solubility” was consistent among laboratories. In 
comparison to the literature-based provisional 2006 WHO BCS classification, three compounds were re-
classified from “high” to “low-solubility”. To estimate the consequences of these experimental solubility 
results on BCS classification, dose-adjusted in silico predictions of the fraction absorbed in humans were 
performed using GastroPlus®. Further expansion of these experimental efforts to qualified APIs from the 
WHO Essential Medicines List is anticipated to empower regulatory authorities across the globe to issue 
scientifically-supported guidance regarding the necessity of performing in vivo bioequivalence studies. 
Ultimately, this will improve access to affordable generic products, which is a critical prerequisite to reach 
Universal Health Coverage. 
©2021 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons 
Attribution license (http://creativecommons.org/licenses/by/4.0/). 
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Introduction 
In a world where one third of the population lacks access to essential medicines [1] and medicines 
represent the largest family expenditure after food, generic competition and differential pricing are major 
drivers to sustain a healthy population, especially in low-income countries [2]. Therefore, the World Health 
Organization (WHO) has identified access to essential medicines as one of its key priorities to meet the 
millennium Sustainable Development Goals and reach Universal Health Coverage. 
In general, regulatory agencies carry the public health responsibility to carefully balance access to and 
safety of medicines within their respective authorities. Successful accomplishment of this objective requires 
risk management strategies that are based on scientifically valid data. The Biopharmaceutical Classification 
System (BCS) introduced in 1995 [3] recognizes the fundamental contribution of aqueous solubility of an 
active pharmaceutical ingredient (API) within the physiologically relevant gastrointestinal pH range and its 
mucosal permeability in governing oral absorption in vivo. Consequently, various regulatory agencies 
around the world have adopted guidances specifying the use of the BCS as a scientific framework to grant a 
waiver of mandatory human in vivo bioequivalence studies for immediate-release solid oral dosage. Hence, 
qualifications defined for a biowaiver directly impact access to and affordability of a finished 
pharmaceutical product while assuring the quality of the medicine. 
The WHO recognizes the possibility of waiving in vivo bioequivalence studies (i.e., biowaiver) as an 
effective regulatory strategy to accelerate development of generic products for eligible APIs in order to 
improve access and save lives. Therefore, as part of its 2006 Guidance on Waiving of Bioequivalence 
Requirements for Immediate-release Oral Solid Dosage Forms, the WHO published a provisional 
classification of APIs based on the 14th WHO Essential Medicines List (EML) with regards to their eligibility 
for a biowaiver. As this initial list was largely based on literature data, which can vary widely due to 
different experimental conditions employed, the WHO Expert Committee on Specifications for 
Pharmaceutical Preparations recommended in 2016 that the WHO revises this list to the current EML [4] 
using experimentally determined laboratory data according to a globally harmonized protocol in order to 
facilitate effective generic development, including regulatory review by national regulatory authorities. 
The primary objective of the WHO biowaiver guidance is to establish a scientific framework whereby the 
risk of bioinequivalence is reduced to an acceptable level. Leveraging an API’s main physicochemical 
characteristics that influence intestinal absorption, its clinical safety and efficacy profile, and comparative 
consideration of the finished pharmaceutical product, it is accepted that an API’s solubility, permeability, 
and comparative dissolution data of the finished pharmaceutical product represent adequate scientific 
evidence to enable an informed decision whether or not a biowaiver could be safely recommended for a 
specific API. Eligible substances are those assigned to Class I (highly soluble and highly permeable) or Class 
III (highly soluble and low permeable) according to the BSC framework [5].The BCS is widely accepted by 
various regulatory authority, including EMA and FDA, and highlights the pivotal role of solubility 
underpinning the biowaiver approach. According to the WHO, an API is considered highly soluble when the 
highest single therapeutic dose (e.g., the maximum dose administered orally at once) as specified in the 
approved product label of the originator is soluble in 250 mL or less of aqueous media over the pH range of 
1.2–6.8 [6]. Comparative dissolution data are expected to be generated by pharmaceutical manufactures 
for eligible finished pharmaceutical product containing the APIs classified within this research project. 
Regulators will assess the similarity in the dissolution profiles generated in order to evaluate a potential 
waiver from in vivo BE studies. 
Following a recommendation from the WHO Expert Committee on Specifications for Pharmaceutical 
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Preparations, the WHO Norms and Standards for Pharmaceuticals team initiated in 2017 the WHO 
Biowaiver Project aimed at revising its 2006 BCS [6]. To support revision of this provisional classification list, 
which was largely based on secondary aqueous solubility references and a diverse array of permeability 
data published in the literature, a global multi-center research team was assembled and tasked to study 
solubility profiles of selected APIs using a harmonized experimental protocol. The project began in 2018 as 
a small-scale pilot (Cycle I) focusing on the development of a universal, scientifically sound methodology to 
consistently assess an API’s solubility within the desired gastrointestinal pH range of 1.2–6.8. Preliminary 
validation of the refined equilibrium solubility protocol was performed by three independent laboratories 
and details of the procedure were published as the “WHO Protocol to conduct equilibrium solubility 
experiments for the purpose of Biopharmaceutics Classification System-based classification of Active 
Pharmaceutical Ingredients for biowaiver”, hereinafter referred as the protocol. To prioritize APIs for the 
second phase of the project (Cycle II), which was intended to compare inter-laboratory variability on API 
solubility assessment and classification using the globally harmonized protocol, the following selection 
criteria were defined [7]: i) API included in medicines listed on the EML; ii) intended to be formulated as 
immediate-release, solid oral dosage forms; iii) relevant to therapeutic areas of major public interest; and 
iv) exhibiting well-characterized physicochemical properties. Pharmaceuticals of primary interest to the 
WHO are those associated with WHO Programs focusing on non-communicable diseases, neglected tropical 
diseases, and maternal-child health, including tuberculosis, malaria, and HIV/AIDS. Candidate APIs for Cycle 
II of the WHO Biowaiver Project were identified through a prioritization exercise in collaboration with the 
WHO Prequalification of Medicines Assessment team. Final selection of the API training set for this study 
was performed after public consultation according to stakeholders’ needs and priorities. Table 1 
summarizes the main properties of the selected APIs that were distributed to 10 different international 
laboratories located in WHO Member States representing the African Region, Region of the Americas, 
South-East Asian Region, European Region, and Western Pacific Region, respectively. 
Experimental 
Materials 
All drug substances used in this study were donated by various suppliers and compliant with compendial 
specifications as outlined in The International Pharmacopoeia [8] and other national or regional 
pharmacopoeias. Each API was provided to multiple laboratories according to a risk-based distribution plan 
that assured experimental solubility assessment by three independent facilities. Controlled substances, 
which are difficult to ship across borders, were measured in two facilities. Table 1 summarizes API-specific 
information regarding therapeutic indication, selected physicochemical properties, and the provisional BCS 
classification assigned by the WHO in 2006 based on solubility and permeability data obtained from the 
primary literature. All chemicals selected for experimental solubility assessments were of high purity or 
analytical grade and were used as received. 
Solubility assessment 
Solubility of the highest therapeutic dose according to the approved label or summary of product 
characteristics of the originator was determined for each API at 37 ± 1 °C in aqueous buffer solutions at pH 
1.2, 4.5, and 6.8 using a globally harmonized protocol [9]. Across the various laboratories engaged in this 
study, equilibrium solubility was quantified by the “shake flask” method supported by a validated, stability-
indicating analytical methodology such as high-performance liquid chromatography.  
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Table 1. Active pharmaceutical ingredients prioritized for WHO BCS classification in Cycle II 
API (solid form 































800 200 III -1.40 225.2 1 
Amoxicillin 
(trihydrate) 
Antibacterials Antibiotics 3000 500 I -1.94 419.5 2 
Azithromycin 
(dihydrate) 
Antibacterials Antibiotics 2000 500 IV/II 3.39 785.0 1 
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-1.34 635.5 1 
a According to the 21stWHO Model List of Essential Medicines (2019) 
b 
According to Summary of Product Characteristics from WHO-PQ or National/Regional Regulatory Authority 
c 
Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms. In: 
WHO Expert Committee on Specifications for Pharmaceutical Preparations: fortieth report. Geneva: World Health Organization; 2006: Annex 8 (WHO 
Technical Report Series, No. 937; https://www.who.int/medicines/areas/quality_safety/quality_assurance/ProposalWaiveVivoBioequivalence-
RequirementsModelListEssentialMedicinesImmediateReleaseSolidOralDosageFormsTRS937Annex8.pdf?ua=1, accessed 4 May 2020). Updated 
requirement in: Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability. In: WHO 
Expert Committee on Specifications for Pharmaceutical Preparations: fifty-first report. Geneva: World Health Organization; 2017: Annex 6 (WHO 
Technical Report Series, No. 1003; https://www.who.int/medicines/areas/quality_safety/quality_assurance/trs1003_annex6.pdf?ua=1, accessed 2 
October 2020). 
d 
In silico log P values predicted using ADMET Predictor® 9.5 (Simulations Plus, Inc., Lancaster, CA) 
e 
The molecular weight corresponds to the solid form of the API used for the solubility experiments as indicated in column 1 of this table. 
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The time required to reach equilibrium was experimentally defined during a preliminary experiment 
performed at the pH value where lowest API solubility was predicted. Subsequently, pivotal experiments 
were initiated in triplicate at pH 1.2, 4.5, and 6.8, respectively, using approximately a 10-50 % excess 
amount of the API estimated to meet the WHO “high solubility” class boundary (see below). Undissolved 
solid was separated by either filtration or centrifugation prior to API quantitation employing a validated, 
stability-indicating analytical methodology. Individual solubility was reported in mg/mL. As specified in the 
WHO Technical Report Series No. 1003 Annex 7 entitled “Multisource (generic) pharmaceutical products: 
guidelines on registration requirements to establish interchangeability” [5], an API is considered “highly 
soluble” when the dose/solubility volume (DSV) representing the volume of liquid necessary to completely 
dissolve the highest single therapeutic dose of the API as recommended by the approved label or summary 
of product characteristics of the originator product is consistently smaller than 250 mL over the entire pH-
range of 1.2 – 6.8. 
Permeability data 
To estimate the consequences of the experimental solubility results generated by this global laboratory 
consortium using the harmonized WHO protocol on BCS classification of each API, it was necessary to 
obtain API-specific permeability data indicative of the fraction absorbed in humans (fa). To limit variability 
and selection bias associated with different experimental conditions used to define API permeability as 
shown by Larregieu and Benet for Caco-2 cell permeability assessment [10], a consistent computational 
simulation approach was implemented using GastroPlus®9.7 (Simulations Plus, Inc., Lancaster, CA) under a 
free academic license. GastroPlus®9.7 is a bottom-up, whole-body physiologically-based pharmacokinetic 
(PBPK) model that uses the Advanced Compartmental Absorption Transit (ACAT) mechanistic absorption 
model to mimic the human intestinal absorption of oral formulations from the GI tract [11]. Simulations 
were conducted for the highest therapeutic dose as well as the highest strength of each API reported in 
Table 1 using the human fasted physiological model for an individual with an average bodyweight of 70 kg 
without enterohepatic recirculation following administration of an immediate release tablet associated 
with a default gastric transit time of 15 min. Gastrointestinal absorption rate in the ACAT model is 
estimated over a physiological pH range of 1.3 – 6.8 employing an absorption scale factor logD model, 
which considers regional permeability according to predicted physiological changes in trans- and 
paracellular transport, anatomical changes in surface area due to the presence of villi and microvilli, and 
gastrointestinal pH gradient. A summary of general input parameters used for this PBPK modeling approach 
is provided in Table 2. API-specific input parameters were generated in silico using the ADMET 
Predictor©v9.5.0.0 (Simulations Plus, Inc., Lancaster, CA). To compare in silico predicted fa values for 
gastrointestinal absorption in humans to clinically determined oral bioavailability data indicative of the 
fraction absorbed in vivo, a literature search was performed in the PubMed database 
(www.ncbi.nlm.nih.gov) using the international nonproprietary name of the selected API in combination 
with one or more of the following search terms: absorption, BCS, bioavailability, fraction absorbed, 
gastrointestinal, isotope, mass balance, oral, and pharmacokinetics. Moreover, publicly available 
documents associated with regulatory approvals of originator and generic drug products for the respective 
API were consulted to collect pertinent in vivo pharmacokinetic information from human trials. 
Statistical analysis 
All experiments were carried out at least in three independent laboratories, and results are reported as 
mean ± standard deviation (SD). Coefficients of variation (%CV) were calculated as 100×SD/mean. 
Statistically significant differences (p<0.05) between groups were evaluated using unpaired Student’s t-test 
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or one-way analysis of variance (ANOVA) where appropriate (Microsoft Excel 2010, Microsoft, Redmond, 
WA). 
Table 2. General Formulation and PBPK Simulation Parameters used as Model Input Variables in 
GastroPlus® 
Input Parameter Value 
Dosage Form 
Dose 
Dose volume [mL] 
Mean precipitation time [s] 
Drug particle density [g/mL] 
Mean particle radius [µm] 
Number of bins 
Shape factor 
Dissolution model 
Bile salt effect 
PBPK model 
Small intestine transit time [h] 
ASF model 
Paracellular model 
Biliary clearance fraction 
Simulation mode 
Simulation time [h] 
Immediate release tablet 









Human fasted (male, 30 years, 70 kg) 
3.2 





Results and discussion 
Complexities of solubility measurements 
A distinct feature of the WHO BCS when compared to other BCS classification systems as defined by 
various regional regulatory authorities is that the WHO classification centers on the highest single oral 
therapeutic dose of each APIs (as recommended by the approved label/summary of product characteristics 
of the originator) to estimate the DSV. The rationale for this definition is that BCS classification is mimicking 
more closely real life conditions and corresponds to the “worst case scenario” when patients are taking the 
therapeutic oral dose prescribed. Moreover, a focus on the highest single oral dose provides the necessary 
flexibility to consider different strengths available on the market when regulatory decisions regarding a 
biowaiver are discussed. Overall, these measures are consistent with the WHO’s priority on facilitating 
access to affordable medicines globally. 
In general, samples are expected to reach equilibrium within 24 hours. However, the time required to 
arrive at equilibrium between solid and dissolved API may be influenced by various experimental factors 
ranging from intrinsic API characteristics, excess of solid included, to the type and speed of agitation 
method used [12]. This may leads to long dissolution times until saturation is reached that carry the risk of 
introducing structural changes in the drug substance when in contact with buffers solutions, including 
transition into a different polymorphic state, salt or solvate. In solution, salt forms are more likely to re-
crystallize resulting in highly stable molecular configurations (i.e., free forms) with significantly altered 
dissolution properties. For ionized molecules, in addition, the propensity for self-aggregation and/or 
complexation is increased while in contact with buffer components. 
The conventional shake-flask method represents the “gold standard” for solubility assessment as it is 
simple and easy to perform and only requires inexpensive instrumentation. When executed according to a 
well-designed protocol, it generally results in high quality data, with standard deviation ≤5 %. However, the 
shake-flask method is also time- and labor-intensive and may consume significant amounts of drug 
substance in order to measure thermodynamic solubility of a highly soluble API in the presence of its solid 
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form. To minimize such constraints, the harmonized protocol defines the highest API concentration for 
pivotal solubility determination in this study to a concentration representing at least twice the highest 
therapeutic dose over 250 mL of buffer. Consequently, the experimentally determined concentration value 
does not represent a true “equilibrium” solubility but rather assures that DSV<1, which is compliant with 
the definition of “high solubility”. 
The results of this global solubility assessment for each API are summarized in Table 3. It is important to 
re-emphasize that individual laboratories did not attempt to quantify the thermodynamic equilibrium 
solubility (i.e., saturation concentration in the presence of excess solid). Therefore, for APIs with high 
solubility, recorded values were measured after complete dissolution of the solid. Consequently, greater 
variability in absolute API concentrations recorded in Table 3 under specified pH conditions is the result of 
different API amounts used for the solubility experiments rather than a demonstration of highly variable 
techniques implemented by the different laboratories.  
Among the 10 APIs that were previously included in the 2006 WHO BCS, which was largely based on 
secondary aqueous solubility references, experimental values reported from three independent 
laboratories unambiguously justified re-classification of aciclovir, amoxicillin, and ethionamide from a “high 
solubility” (HS) to a “low solubility” (LS) drug. The change in classification of amoxicillin and aciclovir was 
related to the solubility assessment performed at the highest therapeutic dose (i.e., 3,000 mg for 
amoxicillin and 800 mg for aciclovir) instead of the highest strength as both drugs exhibit dose-dependent 
solubility profiles [13,14]. 






SD CV% DSV 
Solubility
class 
Aciclovir 1.2 4.14 4.71 113.87 193.44 LS 
  4.5 1.25 1.11 88.96 642.57   
  6.8 1.27 1.10 86.45 628.93   
Amoxicillin 
(trihydrate) 
1.2 9.68 13.84 142.96 206.64 LS 
  4.5 2.78 1.64 58.96 718.17   
  6.8 2.84 2.51 88.38 703.69   
Azithromycin 
(dihydrate) 
1.2 9.51  NA NA  210.39 LS 
  4.5 6.32 4.83 76.42 316.53   
  6.8 6.43 0.08 1.25 310.90   
Cefixime 
(trihydrate) 
1.2 0.72 0.76 106.07 555.56 LS 
  4.5 4.44 4.31 97.12 90.15   
  6.8 7.45 4.43 59.46 53.66   
Codeine (phosphate 
hemihydrate) 
1.2 60.68 42.18 69.52 0.99 HS 
  4.5 66.86 51.12 76.46 0.90   
  6.8 70.38 54.91 78.02 0.85   
Daclatasvir 
(dihydrochloride) 
1.2 88.17 125.07 141.86 0.68 LS 
  4.5 1.78 3.48 195.74 33.72   
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1.2 0.57 0.32 55.56 1402.40 LS 
  4.5 0.19 0.04 23.30 4202.05   
  6.8 0.17 0.03 20.14 4776.12   
Dolutegravir 1.2 0.04 0.03 68.10 1252.09 LS 
  4.5 0.04 0.02 61.99 1273.34   
  6.8 0.05 0.02 44.62 943.99   
Efavirenz 1.2 0.18 0.20 109.87 3331.65 LS 
  4.5 0.20 0.24 115.60 2947.17   
  6.8 0.21 0.24 114.51 2857.39   
Ethionamide 1.2 10.23 12.82 125.24 24.43 LS 
  4.5 0.96 0.16 16.71 259.97   
  6.8 0.51 0.08 15.29 488.28   
Furosemide 1.2 0.01 0.02 137.59 5818.26 LS 
   4.5 0.14 0.05 36.66 558.95   
  6.8 3.74 2.04 54.39 21.37   
Primaquine 
(phosphate) 
1.2 50.51 62.22 123.19 0.30 HS 
  4.5 51.38 63.55 123.67 0.29   
  6.8 48.16 59.06 122.63 0.31   
Pyrimethamine 1.2 1.70 0.85 50.17 44.24 LS 
  4.5 4.91 3.98 80.98 15.27   
  6.8 0.27 0.35 128.09 277.50   
Raltegravir 
(potassium) 
1.2 0.16 0.18 110.85 2513.14 LS 
  4.5 0.17 0.15 91.02 2363.23   
  6.8 0.48 0.56 115.85 826.45   
Rifampicin 1.2 41.36 39.37 95.18 14.51 LS 
  4.5 0.70 0.39 55.54 851.79   
  6.8 1.15 0.61 52.93 521.92   
Tenofovirdisoproxil 
fumarate 
1.2 9.24 12.79 138.44 32.48 HS 
  4.5 3.94 3.46 87.78 76.14   
  6.8 4.35 4.53 104.12 68.97   
a 
Experimental data represent mean values of three individual experiments 
Inter-laboratory reproducibility 
To assess the robustness of the globally harmonized solubility protocol, each API was analyzed by at 
least three different laboratories. The only exception was codeine, which was analyzed by two different 
laboratories due to its controlled substance status that limited distribution across borders. Figure 1 
illustrates the variability in pH-dependent solubility data reported for darunavir, as a representative 
example, which was analyzed by six different laboratories. Laboratory-specific interpretation of 
experimental parameters that were deliberately kept flexible in the globally harmonized protocol to enable 
wide spread adoption across various resource settings [15] introduces unavoidable variability in absolute 
solubility data, ranging between 20-50 %. However, it is important to note that intra-laboratory variability 
was always ≤5 % and the final solubility classification of darunavir as a “low solubility” drug was consistent 
among all laboratories. Similar consistencies were observed for all other APIs (see Supplemental 
Information). 
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Figure 1. Experimental pH-dependent solubility values reported for darunavir by six different laboratories. 
Dotted line represents the class boundary between “high solubility” and “low solubility” for the highest 
therapeutic dose of darunavir (i.e., 800 mg) 
Avdeef and co-workers examined over 800 publications describing equilibrium solubility assessment of 
sparingly soluble ionizable drug-like molecules by the shake-flask and related methods [16]. This 
comprehensive analysis identified many factors that affect the quality of the experimental outcome. 
Among all studies, the reported standard deviation among laboratories varied from 0.17 to 0.58 [17] log 
units with reported values up to 1.48 log units for some sparingly soluble compounds. It is predicted that a 
standardized protocol can control some of this inter-laboratory variability. However, compound-specific 
factors such as formation of polymorphs, hydrates, solvates, amorphous solids, and the impact of 
stereoisomers remain sources for experimental variability despite the best intention for consistent 
experimental execution of a protocol. In contrast, the overall standard deviation among all reported 
solubility values from the different laboratories in this study was 0.83 log units, but 50 % of the API data fell 
within a narrower range of 0.7 log units, which is consistent with previous literature comparisons. Figure 2 
attempts to visualize this inter-laboratory variability by representing the distribution of solubility data as 
coefficient of variation (CV%) in comparison to the average observe value (i.e., 100 %). The absence of a 
defined association between inter-laboratory variability and respective API solubility supports the 
robustness of the globally harmonized protocol. Most importantly, the overall solubility classification based 
on individual solubility data was always consistent among all laboratories indicating that key determinants 
of the experimental approach in this globally harmonized protocol were adequately controlled to allow 
consistent solubility assessment for the purpose of BCS classification. 
To explore the dependence of these solubility assessments on the API source material used for the 
experimental approach, various laboratories received the same API that was provided by two or three 
different suppliers. Figure 3 summarizes the results for rifampicin, which was obtained from three different 
manufacturers and analyzed by two different laboratories. The consistent solubility data obtained for all 
three batches suggest that the physical properties of the API provided by the different suppliers were highly 
similar. This conclusion is consistent with the requirement of this study that all APIs must comply with 
compendial specifications that include physical properties. It is noted that absolute solubility values 
obtained for the different batches of rifampicin at pH 1.2 exhibit greater variability than measured at pH 4.5 
and pH 6.8, respectively. The reason for the higher variability observed at pH 1.2 was probably due to 
chemical instability that was reported by most laboratories analyzing this API. 
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Figure 2. Observed inter-laboratory variability versus average solubility values across experiments 
 
Figure 3. Comparative pH-dependent solubility profile of rifampicin obtained from three different suppliers 
and analyzed by two different laboratories 
Intestinal Permeability 
Harmonization across established biowaiver guidance documents consistently defines the permeability 
class boundary for “high permeability” as the fraction absorbed (fa) ≥85 %. However, different regulatory 
authorities identify either the highest therapeutic dose or the highest marketed formulation strength as the 
relevant dose that should be considered for the purpose of a biowaiver pathway [18]. To explore the 
sensitivity of the BCS classification with respect to the permeability of the oral dose administered, 
computational simulations using GastroPlus® were performed estimating fa for the highest therapeutic 
dose and highest formulation strength of each API. 
The results from this in silico modeling approach that utilized a consistent set of model input variables as 
outlined in Table 2 are summarized in Figure 4. The almost perfect overlay between the two symbols 
representing the different dose levels for most of the selected APIs in this training set suggests that 
biopharmaceutical properties remain quite constant, irrespectively whether the highest therapeutic dose 
or the highest formulation strength is modeled. In the context of the BCS, this result implies that 
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gastrointestinal solubility and permeability remain unchanged within the two different dose levels 
compared. Mechanistically, this dose proportionality also supports the hypothesis that gastrointestinal 
absorption for most of these APIs is predominantly driven by passive diffusion. Interestingly, the visual 
representation of these computational simulations identifies two notable exceptions. The predictions for 
amoxicillin estimate a fa = 43.9 % for the 500 mg strength, whereas the predicted fa for a therapeutic oral 
dose of 3,000 mg is only 40.4 %. Although this small reduction in the predicted fa for 3,000 mg dose may 
need confirmation using a broader set of simulation parameters, it seems consistent with results from 
human pharmacokinetic studies that identified nonlinear absorption kinetics for this penicillin-type 
antibiotic after oral administration [19]. Mechanistic evaluation of intestinal permeation pathways 
contributing to oral absorption of amoxicillin revealed a saturable, capacity-limited component mediated 
by the intestinal oligopeptide transporter, PEPT1 [20]. The second API in this training set predicted to 
exhibit dose-dependent absorption kinetics is rifampicin. For the 300 mg strength, the estimated fa = 65.6 % 
but dramatically decreases to fa= 37.9 for a therapeutic oral dose of 750 mg. Mariappan and Singh assessed 
the mechanisms underlying variable gastrointestinal absorption of rifampicin using a rat model [21]. The 
results from this preclinical study provided evidence for limited transfer of this antituberculosis agent 
across the mucosal barrier in a regio-specific manner (jejunum > ileum) due to significant affinity for 
intestinal efflux systems such as P-glycoprotein. Moreover, it was discovered that transepithelial flux of 
rifampicin in the duodenum increased up to limit of 300 µg/mL and becoming constant thereafter, which is 
indicative of a saturable absorption component such as an influx transporter. Since the predicted fa for 
either the highest therapeutic dose or highest formulation strength of amoxicillin and rifampicin were 
<85 %, both APIs were qualified as “low permeability” drugs when using the computationally predicted 
permeability parameter for the purpose of BCS classification. 
 
Figure 4. Intestinal Permeability Classification. Fraction absorbed in humans after oral administration of an 
immediate-release tablet was predicted for the highest daily dose (red squares) and the highest formulation 
strength (green circles) using GastroPlus®. These simulated predictions were compared with results from 
clinical oral bioavailability studies performed in humans (see Table 3 for references). The “high permeability” 
class boundary at the fraction absorbed (fa) = 85 % is represents by the dashed line 
 
The results from these exploratory in silico permeability predictions using default simulation algorithms 
of GastroPlus© identified seven APIs from this training set, namely codeine, daclatasvir, dolutegravir, 
ethionamide, primaquine, pyrimethamine, and raltegravir as “high permeability” drugs according to the 
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WHO BCS threshold of fa ≥85 %. In comparison to clinically determined human bioavailability (F) data for 
these “high permeability” drugs identified from the primary literature, the variability in the fractions of the 
drug reaching the systemic circulation in vivo (30.0 % ≤ F ≤ 96.0 %) is significantly greater than the 
computationally predicted fraction absorbed using GastroPlus© (95.8 % ≤ fa ≤ 99.8 %). This is an important 
reminder of the critical role of model input data that are used to perform PBPK simulations. GastroPlus© 
was used in this study as an example to illustrate the potential of a bottom-up PBPK simulation tool when 
exploring BCS classification of APIs for which no clinical bioavailability data are available. Nevertheless, 
default simulation parameters as outlined in Table 2 may not adequately represent the specific conditions 
encountered in vivo. This may include important volumetric terms of gastrointestinal segments that can 
affect drug solubility and/or precipitation rate of a free salt form and a solvate. Alternatively, physiological 
contribution of in- and efflux transporters that have the ability to significantly modulate the extent and rate 
at which a drug substance becomes available in the systemic circulation after oral administration (= 
bioavailability) may not be adequately represented by default model parameters. Similarly, gene 
polymorphism responsible for different expression levels of major metabolism enzymes (see Supplemental 
Information) that can lead to variable pre-systemic elimination of the API at the brush-border membrane 
may not be appropriately considered when using default model parameters. Therefore, various research 
groups have already initiated comprehensive research studies to identify critical model input parameters 
that must be defined in order to enhance the in vivo relationship and bioequivalence prediction using PBPK 
absorption models [22,23]. 
API Assignment to WHO Biopharmaceutical Classification System 
The main objective of this study was to validate provisional API classification performed earlier using 
literature-based data (i.e., 2006 WHO BCS) with an updated experimental solubility assessment that was 
based on a globally harmonized protocol. Table 4 summarizes the results from this study and compares 
provisional API assignments to the WHO BCS. 
Completion of equilibrium solubility experiments by a consortium of 10 international laboratories 
located in different WHO Regions provided the scientific basis to change the solubility designation from 
“high solubility” to “low solubility” for aciclovir, amoxicillin, and ethionamide. This result may have been 
the consequence of updated highest therapeutic dose values when compared to the provisional 2006 WHO 
BCS classification. In addition, the results from this study provided qualified solubility data for five APIs (i.e., 
daclatasvir, darunavir, dolutegravir, raltegravir, and tenofovir disoproxil fumarate) that were not 
considered during the previous WHO BCS assignment in 2006. For the remaining six APIs, experimental 
solubility assessment confirmed the earlier solubility classification based on literature data. However, due 
the experimental difficulty to directly assess fa in humans, the research community is faced with 
widespread uncertainty regarding the most appropriate methodology to consistently categorize APIs as 
“high permeability” or “low permeability” drugs [39]. Provisional classification of APIs according to the 
WHO BCS in 2006 [6] was exclusively based on literature data. Ambiguity regarding the permeability 
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Aciclovir 800 III LS LP *20.0 [24] IV 
Amoxicillin 
trihydrate 
3000 I LS LP 45.0 [19] IV 
Azithromycin 
dihydrate 
2000 IV/II LS LP *37.0 [25] IV 
Cefixime trihydrate 400 IV LS LP 40.2 [26] IV 
Codeine phosphate 
semihydrate 
60 III HS HP 54.8 [27] I/III 
Daclatasvir 
dihydrochloride 
60 Not classified LS HP 67.0 [28] II/IV 
Darunavir 
ethanolate 
800 Not classified LS LP *37.0 [29] IV 
Dolutegravir 50 Not classified LS HP 31.0 [30] II/IV 
Efavirenz 600 II/IV  LS LP 19.5 [31] IV 
Ethionamide 500–1000 III/I LS HP *83.3 [32] II/IV 
Furosemide 80 IV/II LS LP *42.8 [33] IV 
Primaquine 
phosphate 
15 I HS HP 96.0 [34] I 
Pyrimethamine 75 IV/III LS HP *50.0 [35] II/IV 
Raltegravir 
potassium 
400 Not classified LS HP 30.0 [36] II/IV 




300 Not classified HS LP 25 [38] III 
a
According to Summary of Product Characteristics from WHO-PQ or National/Regional Regulatory Authority. 
b Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms. In: 
WHO Expert Committee on Specifications for Pharmaceutical Preparations: fortieth report. Geneva: World Health Organization; 2006: Annex 8 
(WHO Technical Report Series, No.  937; 
https://www.who.int/medicines/areas/quality_safety/quality_assurance/ProposalWaiveVivoBioequivalenceRequirementsModelListEssentialMedici
nesImmediateReleaseSolidOralDosageFormsTRS937Annex8.pdf?ua=1, accessed 4 May 2020). Updated requirement in: Multisource (generic) 
pharmaceutical products: guidelines on registration requirements to establish interchangeability. In: WHO Expert Committee on Specifications for 
Pharmaceutical Preparations: fifty-first report. Geneva: World Health Organization; 2017: Annex 6 (WHO Technical Report Series, No. 1003; 
https://www.who.int/medicines/areas/quality_safety/quality_assurance/trs1003_annex6.pdf?ua=1, accessed 2 Oct 2020). 
C oral bioavailability data were obtained from the primary literature. 
LS = low solubility; HS = high solubility; LP = low permeability; HP = high permeability 
* clinical bioavailability data using an oral dose different than the highest therapeutic dose listed in Table 1 
To explore alternative options that may overcome limitations of literature-based permeability 
classification, various research groups have reported the use of computational PBPK absorption models for 
bioequivalence predictions [22,23]. In this study, the GastroPlus© platform was used as an example to 
illustrate the potential of a bottom-up PBPK simulation tool when exploring BCS classification of APIs, 
particularly in situations when clinical bioavailability data are not available. The results from this in silico 
exercise are consistent with previous literature-based permeability assignments for aciclovir, furosemide, 
and primaquine. Furthermore, adoption of this a priori modeling approach using default GastroPlus© input 
parameters (see Table 2), combined with clinical bioavailability data generated for different oral doses, 
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made it feasible to define with high confidence permeability for darunavir and tenofovir disoproxil, which 
were not considered during the previous WHO BCS assignment in 2006. Similarly, using the same consensus 
approach that compares the in silico predicted fa in humans and clinically determined bioavailability data 
for the same API but measured at different doses, the ambiguous BCS classification of azithromycin, 
efavirenz, and furosemide were clarified. However, the results summarized in Table 4 clearly underline 
significant discrepancies between PBPK-predicted human absorption data and clinically measured 
bioavailability values, specifically for codeine, dolutegravir, ethionamide, pyrimethamine, raltegravir, and 
rifampicin. For some of those APIs, such as rifampicin, which has been described to experience regio-
specific absorption (jejunum > ileum) due to significant affinity for intestinal efflux systems such as P-
glycoprotein [21], the literature may provide clues for a reasonable scientific hypothesis that could explain 
these inconsistent results. For other APIs, scientific explanations are less clear and may require further 
exploration using carefully designed experimental approaches to assess permeability. It is generally 
assumed that physiologically-based in silico absorption models are promising supplemental tools to 
traditional in vitro assays and preclinical in vivo studies. However, as recently reported by Sjögren and 
colleagues [40], different modeling platforms are associated with inconsistent over- and under-prediction 
of the fraction absorbed. Consequently, a broader data mining approach will be necessary to maximize 
confidence in model performance. 
Conclusions 
The results from this study demonstrate successful validation of a globally harmonized solubility 
protocol across different international laboratories to support WHO BCS classification. Implementation of a 
consensus approach that compares in silico predicted fa in humans using the GastroPlus
© PBPK simulation 
platform and clinically determined bioavailability data for the same API but measured at different doses 
enabled unambiguous assignment of 10 out of the 16 APIs selected for this pilot study to one of the four 
BCS classes. Further expansion of these experimental efforts to qualified APIs from the WHO Essential 
Medicines List is predicted to provide regulatory authorities across the globe with scientifically validated 
data to support decisions regarding the need for in vivo bioequivalence studies. Ultimately, this will 
improve access to affordable generic products, which is a critical prerequisite to reach Universal Health 
Coverage. 
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